# Reflect Scientific, Inc.: financial statements, quarterly

RSCF · OTC · CIK 1103090 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rscf.md) · [Financials](/companies/rscf/financials.md) · [Filings](/companies/rscf/filings.md) · [Insiders](/companies/rscf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rscf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [829 d](/filings/0001548123-23-000056.md) | [754](/filings/0001548123-23-000102.md) | [556](/filings/0001548123-23-000137.md) | [253](/filings/0001548123-23-000167.md) | [479 d](/filings/0001548123-24-000032.md) | [241](/filings/0001548123-24-000073.md) | [124](/filings/0001548123-24-000101.md) | [526](/filings/0001548123-24-000126.md) | [189 d](/filings/0001548123-24-000032.md) | [429](/filings/0001548123-24-000073.md) | [590](/filings/0001548123-24-000101.md) | [514](/filings/0001548123-24-000126.md) |
| Cost of revenue | $k | [263 d](/filings/0001548123-23-000056.md) | [234](/filings/0001548123-23-000102.md) | [196](/filings/0001548123-23-000137.md) | [122](/filings/0001548123-23-000167.md) | [270 d](/filings/0001548123-24-000032.md) | [114](/filings/0001548123-24-000073.md) | [63.9](/filings/0001548123-24-000101.md) | [196](/filings/0001548123-24-000126.md) | [110 d](/filings/0001548123-24-000032.md) | [187](/filings/0001548123-24-000073.md) | [232](/filings/0001548123-24-000101.md) | [186](/filings/0001548123-24-000126.md) |
| Gross profit | $k | [566 d](/filings/0001548123-23-000056.md) | [519](/filings/0001548123-23-000102.md) | [360](/filings/0001548123-23-000137.md) | [131](/filings/0001548123-23-000167.md) | [209 d](/filings/0001548123-24-000032.md) | [127](/filings/0001548123-24-000073.md) | [60.5](/filings/0001548123-24-000101.md) | [330](/filings/0001548123-24-000126.md) | [78.4 d](/filings/0001548123-24-000032.md) | [242](/filings/0001548123-24-000073.md) | [359](/filings/0001548123-24-000101.md) | [328](/filings/0001548123-24-000126.md) |
| Research and development | $k | [12.6 d](/filings/0001548123-23-000056.md) | [25.3](/filings/0001548123-23-000102.md) | [18.3](/filings/0001548123-23-000137.md) | [14.8](/filings/0001548123-23-000167.md) | [15.0 d](/filings/0001548123-24-000032.md) | [6.1](/filings/0001548123-24-000073.md) | [5.4](/filings/0001548123-24-000101.md) | [9.1](/filings/0001548123-24-000126.md) | [9.0 d](/filings/0001548123-24-000032.md) | [7.4](/filings/0001548123-24-000073.md) | [4.6](/filings/0001548123-24-000101.md) | [3.1](/filings/0001548123-24-000126.md) |
| Operating income | $k | [361 d](/filings/0001548123-23-000056.md) | [207](/filings/0001548123-23-000102.md) | [78.1](/filings/0001548123-23-000137.md) | [(133)](/filings/0001548123-23-000167.md) | [(61.3) d](/filings/0001548123-24-000032.md) | [(148)](/filings/0001548123-24-000073.md) | [(181)](/filings/0001548123-24-000101.md) | [80.9](/filings/0001548123-24-000126.md) | [(220) d](/filings/0001548123-24-000032.md) | [(40.5)](/filings/0001548123-24-000073.md) | [98.3](/filings/0001548123-24-000101.md) | [99.2](/filings/0001548123-24-000126.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | [0.7](/filings/0001548123-23-000167.md) | [0.0 d](/filings/0001548123-24-000032.md) | not reported | [0.3](/filings/0001548123-23-000137.md) | [0.0 d](/filings/0001548123-24-000126.md) | [0.0 d](/filings/0001548123-24-000032.md) | not reported | not reported | [0.1](/filings/0001548123-24-000126.md) |
| Net income | $k | [361 d](/filings/0001548123-23-000056.md) | [207](/filings/0001548123-23-000167.md) | [78.1](/filings/0001548123-23-000167.md) | [(134)](/filings/0001548123-23-000167.md) | [(61.3) d](/filings/0001548123-24-000032.md) | [(148)](/filings/0001548123-24-000126.md) | [(181)](/filings/0001548123-24-000126.md) | [86.3](/filings/0001548123-24-000126.md) | [(216) d](/filings/0001548123-24-000032.md) | [(32.0)](/filings/0001548123-24-000126.md) | [109](/filings/0001548123-24-000126.md) | [110](/filings/0001548123-24-000126.md) |
| Diluted EPS | $ per share | not reported | [0.00](/filings/0001548123-23-000102.md) | [0.00](/filings/0001548123-23-000137.md) | [0.00](/filings/0001548123-23-000167.md) | not reported | [0.00](/filings/0001548123-24-000073.md) | [0.00](/filings/0001548123-24-000101.md) | [0.00](/filings/0001548123-24-000126.md) | not reported | [0.00](/filings/0001548123-24-000073.md) | [0.00](/filings/0001548123-24-000101.md) | [0.00](/filings/0001548123-24-000126.md) |
| Basic EPS | $ per share | not reported | [0.00](/filings/0001548123-23-000102.md) | [0.00](/filings/0001548123-23-000137.md) | [0.00](/filings/0001548123-23-000167.md) | not reported | [0.00](/filings/0001548123-24-000073.md) | [0.00](/filings/0001548123-24-000101.md) | [0.00](/filings/0001548123-24-000126.md) | not reported | [0.00](/filings/0001548123-24-000073.md) | [0.00](/filings/0001548123-24-000101.md) | [0.00](/filings/0001548123-24-000126.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [1,474](/filings/0001548123-22-000034.md) | [1,580](/filings/0001548123-22-000067.md) | [1,248](/filings/0001548123-22-000114.md) | [1,325](/filings/0001548123-22-000178.md) | [1,382](/filings/0001548123-24-000032.md) | [1,199](/filings/0001548123-23-000102.md) | [1,409](/filings/0001548123-23-000137.md) | [1,339](/filings/0001548123-23-000167.md) | [1,278](/filings/0001548123-24-000126.md) | [1,009](/filings/0001548123-24-000073.md) | [1,103](/filings/0001548123-24-000101.md) | [1,030](/filings/0001548123-24-000126.md) |
| Current assets | $k | [2,305](/filings/0001548123-23-000056.md) | [2,512](/filings/0001548123-22-000067.md) | [2,645](/filings/0001548123-22-000114.md) | [2,360](/filings/0001548123-22-000178.md) | [2,329](/filings/0001548123-24-000032.md) | [2,164](/filings/0001548123-23-000102.md) | [2,402](/filings/0001548123-23-000137.md) | [2,390](/filings/0001548123-23-000167.md) | [2,370](/filings/0001548123-24-000126.md) | [2,396](/filings/0001548123-24-000073.md) | [2,064](/filings/0001548123-24-000101.md) | [2,093](/filings/0001548123-24-000126.md) |
| Total assets | $k | [2,479](/filings/0001548123-23-000056.md) | [2,672](/filings/0001548123-22-000067.md) | [2,791](/filings/0001548123-22-000114.md) | [2,491](/filings/0001548123-22-000178.md) | [2,446](/filings/0001548123-24-000032.md) | [2,267](/filings/0001548123-23-000102.md) | [2,491](/filings/0001548123-23-000137.md) | [2,706](/filings/0001548123-23-000167.md) | [2,669](/filings/0001548123-24-000126.md) | [2,677](/filings/0001548123-24-000073.md) | [2,327](/filings/0001548123-24-000101.md) | [2,338](/filings/0001548123-24-000126.md) |
| Current liabilities | $k | [242](/filings/0001548123-23-000056.md) | [230](/filings/0001548123-22-000067.md) | [286](/filings/0001548123-22-000114.md) | [130](/filings/0001548123-22-000178.md) | [150](/filings/0001548123-24-000032.md) | [111](/filings/0001548123-23-000102.md) | [509](/filings/0001548123-23-000137.md) | [434](/filings/0001548123-23-000167.md) | [596](/filings/0001548123-24-000126.md) | [655](/filings/0001548123-24-000073.md) | [216](/filings/0001548123-24-000101.md) | [139](/filings/0001548123-24-000126.md) |
| Total liabilities | $k | [299](/filings/0001548123-23-000056.md) | [273](/filings/0001548123-22-000067.md) | [313](/filings/0001548123-22-000114.md) | [140](/filings/0001548123-22-000178.md) | [150](/filings/0001548123-24-000032.md) | [111](/filings/0001548123-23-000102.md) | [509](/filings/0001548123-23-000137.md) | [632](/filings/0001548123-23-000167.md) | [776](/filings/0001548123-24-000126.md) | [816](/filings/0001548123-24-000073.md) | [357](/filings/0001548123-24-000101.md) | [259](/filings/0001548123-24-000126.md) |
| Shareholders' equity | $k | [2,180](/filings/0001548123-24-000032.md) | [2,399](/filings/0001548123-23-000167.md) | [2,478](/filings/0001548123-23-000167.md) | [2,351](/filings/0001548123-23-000167.md) | [2,297](/filings/0001548123-24-000126.md) | [2,156](/filings/0001548123-24-000126.md) | [1,981](/filings/0001548123-24-000126.md) | [2,075](/filings/0001548123-24-000126.md) | [1,893](/filings/0001548123-24-000126.md) | [1,861](/filings/0001548123-24-000126.md) | [1,970](/filings/0001548123-24-000126.md) | [2,080](/filings/0001548123-24-000126.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [330 d](/filings/0001548123-23-000056.md) | [106](/filings/0001548123-23-000102.md) | [(332) d](/filings/0001548123-23-000137.md) | [77.0 d](/filings/0001548123-23-000167.md) | [57.2 d](/filings/0001548123-24-000032.md) | [(183)](/filings/0001548123-24-000073.md) | [210 d](/filings/0001548123-24-000101.md) | [(69.3) d](/filings/0001548123-24-000126.md) | [(61.5) d](/filings/0001548123-24-000032.md) | [(179)](/filings/0001548123-24-000073.md) | [3.3 d](/filings/0001548123-24-000101.md) | [(72.3) d](/filings/0001548123-24-000126.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [84.7](/filings/0001548123-22-000067.md) | [84.7](/filings/0001548123-22-000114.md) | [84.7](/filings/0001548123-22-000178.md) | [85.7](/filings/0001548123-23-000102.md) | [85.7](/filings/0001548123-23-000137.md) | [85.0](/filings/0001548123-23-000167.md) | [85.2](/filings/0001548123-24-000073.md) | [85.2](/filings/0001548123-24-000101.md) | [85.7](/filings/0001548123-24-000126.md) | [85.7](/filings/0001548123-24-000073.md) | [85.7](/filings/0001548123-24-000101.md) | [85.7](/filings/0001548123-24-000126.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 85,664,086 at 2024-11-08, from the cover of the [10-Q filed 2024-11-12](/filings/0001548123-24-000126.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.